BCD方案与VAD方案对多发性骨髓瘤的疗效及对血M蛋白、β2–MG的影响

Curative Effect of BCD Regimen and VAD Regimen in the Treatment of Multiple Myeloma and the Influence on Blood M Protein and β2-MG

目的:探究BCD方案(硼替佐米+环磷酰胺+地塞米松)和VAD方案(长春新碱+多柔比星+地塞米松)治疗多发性骨髓瘤(MM)的疗效及对血M蛋白、β2微球蛋白(β2-MG)的影响。方法:选取2016年1月至2019年12月平顶山市第一人民医院收治的52例初诊MM患者作为研究对象,根据治疗方法分为VAD组(22例)和BCD组(30例)。比较两组不同疗法的治疗效果以及患者治疗前后血液中M蛋白、β2微球蛋白(β2-MG)和血红蛋白含量的变化。结果:BCD组患者的总缓解率(ORR)为86.67%,高于VAD组的59.09%,差异具有统计学意义(P<0.05)。治疗后,两组患者血M蛋白、β2-MG水平均较治疗前降低,且BCD组低于VAD组,差异具有统计学意义(P<0.05);治疗后,两组患者血红蛋白水平均较治疗前升高,且BCD组高于VAD组,差异具有统计学意义(P<0.05)。结论:BCD方案治疗MM患者综合价值优于VAD方案,它可以降低血液中的M蛋白、β2-MG水平,提高血红蛋白水平。

Objective To explore the curative effect of BCD regimen (bortezomib +cyclophosphamide+dexamethasone) and VAD regimen (vincristine+doxorubicin+dexamethasone) regimen in the treatment of multiple myeloma (MM),and the influence on blood M protein and β2 microglobulin (β2-MG).Methods A total of 52 patients with newly diagnosed MM admitted to Pingdingshan First People’s Hospital were selected as the research subjects between January 2016 and December 2019.They were divided into VAD group (n=22) and BCD group (n=30) according to the treatment method.Therapeutic effects and changes in blood M protein,β2-MG and hemoglobin levels before and after treatment were compared between the two groups.Results The objective response rate (ORR) in BCD group was higher than that in VAD group (86.67% vs.59.10%) (P < 0.05).After treatment,blood M protein and β-MG levels were reduced in the two groups,and the two in BCD group were lower than those in VAD group (P < 0.05).After treatment,hemoglobin levels in the two groups were increased,and BCD group had higher level than VAD group(P < 0.05).Conclusion Overall,BCD regimen is superior to VAD regimen in the treatment of patients with MM.It can lower the levels of blood M protein and β2-MG,and increase hemoglobin level.